Clinical experience of using oncotype DX as an additional treatment decision tool in early breast cancer - A retrospective analysis from 5 Greek institutions

European Journal of Surgical Oncology

Volumn 38, Issue 5, 2012, Pages 413-419

  Markopoulos, C ^a   Xepapadakis, Gr ^a   Venizelos, V ^a   Tsiftsoglou, A ^a   Misitzis, J ^a   Panoussis, D ^a   Antonopoulou, Z ^a   Stathoulopoulou, M ^a   Zobolas, V ^a   Gogas, H ^a  

^a Hellenic Society of Breast Surgeons   (Greece)

Author keywords

Adjuvant; Breast cancer; Chemotherapy; Estrogen receptor positive; Multigene assay; Recurrence score

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CLINICAL DECISION MAKING; DECISION SUPPORT SYSTEM; EARLY CANCER; EARYL BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RECURRENCE SCORE; SCORING SYSTEM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MEDICAL RECORDS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84859425797     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2012.02.183     Document Type: Article

References (26)

1. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34. (Pubitemid 46622311)
2. Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer. Ann Oncol 2009;20:1319-29.
3. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
4. Albain K, Barlowe W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomized trial. Lancet Oncol 2010;11:55-65.
5. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312. (Pubitemid 350232263)
6. NCCN. Clinical practice guidelines in oncology breast cancer (Version 1.2011). http://www.NCCN.org.
7. Aebi S, Davidson T, Gruber G, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Ann Oncol 2010;21(Supp. 5):v9-v14.
8. Goldhirsch A, Wood C, Coates AS. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011;22:1736-47.
9. Rezai M, Eiermann W, Kümmel S, et al. Impact of the recurrence score on adjuvant decision-making in ER-Positive early breast cancer: results of a large prospective multicentre decision impact study in node negative and node positive disease. In: poster presented at the San Antonio breast cancer Symposium 2011, #P2-12-26.
10. Lo S, Mumby P, Norton J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010;28:1671-6.
11. Albanell J, Gonzales A, Ruiz-Borrego M, et al. Prospective transGEICAM study of oncotype DX® in clinical decision making in women with estrogen receptor-Positive. Node-Negative Breast Cancer Ann Oncol 2011;. [June 6 epub ahead of print].
12. Holt SDH, Durrani S, Pudney D, et al. Results from a prospective clinical study on the impact of Oncotype DX® on adjuvant treatment decision in a cohort of 142 UK patients. In: poster presented at the San Antonio Breast Cancer Symposium 2011 #P5-14-26.
13. Yamauchi H, Nakagawa C, Yamashige S, et al. Decision impact and economic evaluation of the 21-gene Recurrence Score® assay for physicians and patients in Japan. In: poster presented at the Annual European Society for medical oncology Congress, September 2011; [Stockholm, Sweden].
14. de Boer RH, Baker C, Speakman D, Mann B. Australian Decision Impact Study: the impact of Oncotype DX Recurrence Score (RS) on adjuvant treatment decisions in hormone receptor positive (HR+), node negative and node positive (N+) early breast cancer (ESBC) in the multidisciplinary clinic. In: poster presented at the San Antonio Breast Cancer Symposium 2011, #P4-09-18.
15. Ademuyiwa FO, Miller A, O'Connor T, et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multiinstitutional breast cancer cohort. Breat Cancer Res Treat 2011;126:797-802.
16. Hornberger J, Chien R. Meta-analysis of the decision impact of the 21-gene breast cancer recurrence score in clinical practice. In: poster presentation at the 12th St. Gallen International breast cancer Conference 16-19 March 2011, St. Gallen, Switzerland.
17. Collins LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol 2005;123:16-20. (Pubitemid 40066167)
18. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and nodepositive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010;28:1829-34.
19. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 2008;26:4063-71.
20. Kamal AH, Loprinzi CL, Reynolds C, et al. Breast medical oncologists'use of standard prognostic fators to predict a 21-gene recurrence score. Oncologist 2011;16:1359-66.
21. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol 2011;29:4273-8.
22. Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
23. Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
24. Sahebjam S, Aloyz R, Pilavdzic D, et al. Ki 67 is a major, but not the sole determinant of oncotype DX recurrence score. Br J Cancer 2011;105:1342-5.
25. Liebermann N, Baehner FL, Soussan-Gutman L, et al. Evaluation of the recurrence score, nodal status and traditional Clinicopathologic metrics in a large ER-Positive patient cohort. In: poster presented at the Annual European Society for medical oncology Congress, September 2011; [Stockholm, Sweden].
26. Degenhardt T, Gluz O, Kreipe HH, et al. Prospective comparison o recurrence Score, uPA/PAI-1, central grade and molecular classification in early breast cancer: interim results from the WSG-Plan B trial. J Clin Oncol 2011;29. [suppl; abstr 10594].